“The only people who understand traders are other traders”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Getting ready for the break out .$$$$$$$$$$$$$$
Japan Aerospace Exploration Agency) for the second phase of evaluation for deep space mission, as well as the securing of a major contract from an Asian-based customer. Additionally, our recent progress of being the first and only flexible CIGS manufacturer to have achieved ISO 9001:2015 certification, will enable us to serve a larger universe of premium market customers who prefer products manufactured under a superlative Quality Management System and must be as robust and fail proof as possible."
http://global.jaxa.jp/
Ascent Solar Can't wait to see the close on this today . Holding and waiting.
Victor Lee salary 2016. $375,000.00
Do the math number of outstanding shares times a dollar and you'll have your answer about whether the stock will ever be in a dollar again.
CVM very nice chance we can have some price stability moving bullish and staying above .12 slow climbing to .20 even without any news about FDA Hold the The fact that they got the new patent and they already have the manufacturing facility and they're in the testing phase does not mean that they need FDA approval to you even administer the medication and other countries so I am very confident with the stocks ability to see quite a recovery and move back out of the penny range.
Descend Solar
Looks like we could be seeing a big move coming this is good for anyone looking catch a nice bounce we could hit .008 before Friday even might have a spike to .01 Day traders with small positions are going be eating this up like pac-Man. Because of the volume and ability rapid price fluctuations small amount of money can be made quickly . Not talking big money but enough to make a little trip somewhere on an airplane.
Gap Down and Fill or gap and Crap ??
Could this be a shorts trap .
Gevo, Inc. (NASDAQ:GEVO) opened at 1.28 on Tuesday. The firm’s market cap is $8.42 million. Gevo, Inc. has a 12-month low of $0.92 and a 12-month high of $27.20. The firm’s 50-day moving average price is $1.37 and its 200 day moving average price is $5.17.
CVM. Should hit $.11-$.12 today
But I can't tell you how to LCA $.11-$.12 cents
It all depends on how I feel . Sometimes I have a really good sense of what's going on . Other times it's more like Rainman at Kmart
I said this is total bull Loney
True this stock is no a pump and dump it has been selected twice OTC market top 50 this is nothing to be taken lightly . As far as the lithium Junior mining company with a plan and a potential for upswing this company definitely has a great long-term potential for a smart investor was willing to sit it out like there is a few on this board parking is safe percentage of their cash is definitely not going to kill them . And at the current price right now reloading might even be considered A good choice . Multiple occasions to stock his bounce back over $.76 cents and that current price that's a pretty nice gain . I'm definitely looking again. Thinking about dropping in 5K if it's. .57 cents I do believe a buy order will triggered ??. 8700 share at .76 would be over 1500.00 that's definitely more than a couple ?? and if I'm able to hold with a nice stop loss and this baby decides to hit a dollar then we know the math get it's easy 8700.00 3700.00 definitely find me a patriots ticket or two .
Look back at Gild Stock under .60 cents 1992 and now look . This is how pharmaceutical companies are . This company's position to sell for the long run . The injection technology therapy and addition to the fully operational and FDA approved manufacturing facility doesn't mean it has to have a approval of this particular drug . LEAPS and the other applications of
RESULTS: Leukocyte interleukin injection treatment induced a shift from stromal infiltrating T cells toward intraepithelial T cells and posted a significant (P <.05) increase in intraepithelial CD3-positive T cells independent of the leukocyte interleukin injection dose, whereas the increase in CD25 (interleukin-2 receptor alpha [IL-2Ralpha])-positive lymphoid cells was significant only at the lowest leukocyte interleukin injection dose (P <.05). Furthermore, both low- and medium-dose leukocyte interleukin injection treatment induced a significant (P <.05) increase in the number of cycling tumor cells, as compared with control values.
CONCLUSION: The results could be highly beneficial for patients with oral squamous cell carcinoma. First, leukocyte interleukin injection treatment induces T-cell migration into cancer nests and, second, noncycling cancer cells may enter cell cycling on administration of leukocyte interleukin injection. This latter effect may modulate the susceptibility of cancer cells to radiation therapy and chemotherapy. The findings may indicate a need to re-evaluate the way in which follow-up treatment (with radiation therapy and chemotherapy) of patients with head and neck cancer is currently approached.
This is a technique that has not been used by any others it's also a patented form of injection on-site treatment which can be used in other applications. Approval by the FDA of their stage III drug. Would not only skyrocket this stock but you're talking about. Billions of dollars 75 million . Now when you read the prospectus and you see how much money Company insiders have invested in addition to every time they have a meeting. Voting for share distribution into their pension and salary pretty much indicated they also understand the implications of approval or being bought out. Or even a merger with a similar type of company using their packing facility manufacturing equipment . This company is been headlined on mainstream news and even though it's has mass dilution in reverse stock split all this is minuscule to the amount of upswing return . The long game on this company in returns can result the Mucho dollars for the smart investor . This company also provides a great day trading platform because of the volume in the very sweet spot of the under $.10 stock price . There might be a regression with the approval of a reverse but again or they're actually could be a spike . Either way you look at it if your shorting or going on very enticing . For example $1000 at current prices would roughly game you 11,000 shares . Assuming they did a reverse split say one 1 - 20 we leave the stock holder at 550 shares say at 2.00 a share after the split . If that stock ended up at 1.00 your looking at 50 % digress if the stock ends up going up to 3.00 then you have a 50% increase . If the stock drug gangs approval meet compliance and continues to grow or merges is bought out you can see the stock anywhere between two dollars a share and $60 a share within 10 years . Assuming it for the same pattern as GILD that Same $1000 invested in 2017 11,000 share after a 1/20 split 550 shares at say stock price of 60.00 dollars would be worth in 2027 33,000 dollars. Not too bad for waiting 10 years worst-case and you lose 1000 bucks . depending on your Nest egg now if you invest 1% of $100,000 I will be 1000 . I'm going to try $5,000 and I will post back in the year 2027 and if I'm correct should have roughly $160,000 no this is hypothetical speculation and compete Boo cocky .
Deak foresees the Nevada project possibly being in operation . Possibly that's been the theme of Nevada with you being extracted from Clay .
I would just be more concerned that they're just pumping The Nevada site tactic used before . The only place that money to going to be coming from is the SQM deal . And that's just going to be producing for them in order to be the stainable .
Buy out maybe ?
:)
Seems like thats correct
Gevo Bottom or Bust ? I am thinking this has just about hit the Bottom the shorts have had there belly filled since this Stocks IPO I think we will start to see a price move back to above 2.00 before March, 2017
Analysts have set a twelve-month consensus price objective of $11.00 for the company and are predicting that the company will post ($0.96) EPS for the current quarter, according to Zacks. Zacks has also given Gevo an industry rank of 68 out of 265 based on the ratings given to its competitors.
It's not dilute The shares a restricted and you're not being added read the filing
GEVO price target of $8.50 and a 52-week trading range of $1.33 to $27.20
They have to post this standard SEC required under risk . And this is a possibility that can happen to any stock . They are not near that process yet there will be a few more catalyst that would have to occur .
The stock is almost been a perfect short from the time it was offered . But if you look at the institutional investors there's not a huge amount but there has been recent activity . And the insider activity has also been steady . With an additional contract or pricing change in the industry or some governmental contract intervention and a news release The explosive rebounding that could occur could smash remaining shorts or greedy Shorters . Which could make for an epic Single day spike even a retrace The lower level would put it at $2.33 that would be 75% to 100% return if people were buying in at these prices they were able to ride that wave and get out. If this occurs .
There can be no assurance that we will be able to raise additional funds, restructure our indebtedness or achieve or sustain profitability or positive cash flows from operations.... If we are unable to implement a recapitalization or restructuring transaction ... we will have to seek other strategic alternatives, including other sources of financing and, if unsuccessful, may be forced to seek the protection of bankruptcy court by filing for bankruptcy," according to the SEC filing.
Rodman & Renshaw Price Target $12.00 from $4.00
Many Gevo, Inc.(GEVO) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Company shares were Reiterated by Rodman & Renshaw on Jan 13, 2017 to Buy, Raises Price Target to $ 12 from a previous price target of $4 .
Company has reported several Insider transactions to the SEC, on Feb 14, 2017, Mike Willis (CFO) sold 2 shares at 2.51 per share price.On Feb 14, 2017, Gregory Roda (Chief Commercial Officer) sold 1 shares at 2.51 per share price.On Feb 14, 2017, Patrick R. Gruber (Chief Executive Officer) sold 6 shares at 2.51 per share price.
I have take many a loss but I have a positive return and have Survived to live another day . The best you can Ask for .
I knew it was about to pop even on my cloud trading I could tell .
Ballistic is very easily obtainable at these levels with minor news . You could easily see 100 % to 400 % in a single day of favorable FDA removal . This has private institutional investors that are in for a much higher price . Share prices been driven down by management and dilution just in order for them to stay in operations there's nothing preventing this from moving way out which way to go ballistic .
Your wrong . I particular 20% gain. And that happen . I also predicted ballistic . And that is happening based on the definition of ballistic projectile. So I am correct and I have profited thank you very much .
And Thank you I was correct Again.
this is good new for me I will be buying at the gap down and yes its going be a nice Gap and Fill .
I am buying thank you sellers .
At daytrading to risky to but being in a pennystock OTC is risky . i'm in there's a lot of other pharmaceuticals you can invest in.
To make money stock trading you don't even need a single product. But I guess if you're into productivity in the actual company then sure yeah you need a product .
Clay is only is doing chart research in my personal opinion . And sometimes I think he totally sucks at it . I doubt he's reading any of the filings . 10 Q 8 Form 4 or anything pertaining to the stock: charting signaling and technical analysis are good for treating. Deeper research is also very valuable when trying to determine the shake out price over a period of time. Not just in minutes or days when it comes to daytraders . It's clear to me that the stock will revisit at least the 1.04 1.07 range within the monthly.
And in my opinion a true classification of the pump and dump isn't so much based on the elevated then reduced price as it is more based on Hyperinflated news events fake news troll spam large targeted trades . But with this stock at its current price and the float any large volume makes it to mend this ripple in a small pond sometimes those ripples will settle right where they started from or below .
You can't hinge everything up on the FDA's approval or disapproval of this particular drug at stage III. There's more to CVM then just this particular drug . FDA approval. If you read the 10-Q not only does the company have a functional approved manufacturing facility. Which can make the stock very ripe for an accusation . LEAPs it's also only in stage one. Stage two news is usually where micro bio pharmaceutical stocks really see their stock movement. At this low price you could easily see 100% to 40% returns within a week based on any variable change-.
I was spot on with my prediction. I know I could've been 50-50 but I was pretty confident that that will be the result yesterday. And I was able to make a 10% profit. And I still have a large long position. I Stillview this company as an outside horse and a long race. But believe me the profitability of this could be extremely valuable. The patent proprietary technology of injection medication therapy directly treating. Is the next generation of medication delivery. And with that manufacturing company if they survive throughout this process they will come out the other end Winning. Which hopefully result in shareholder benefits.
CVM stock 20% from this price without blinking the eye and we could revisit higher prices based on any news developments . The stock is going to attract attention very fast with traders . .48 cents is 100 % Return. 1000.00 investment could be worth 100,000.00 easily with the stock got a long with any successful outcome.
CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis.
$0.125 to $0.20 per share. stock will see this soon
December 8, 2016, the Company sold 34,024,000 shares of common stock and warrants to purchase common stock at a price of $0.125 in a public offering. The warrants consist of 17,012,000 Series CC warrants to purchase 17,012,000 shares of common stock, 34,024,000 Series DD warrants to purchase 34,024,000 shares of common stock and 34,024,000 Series EE warrants to purchase 34,024,000 shares of common stock. The Series CC warrants are immediately exercisable, expire in five-years and have an exercise price of $0.20 per share. The Series DD warrants are immediately exercisable, expire in six-months and have an exercise price of $0.18 per share. The Series EE warrants are immediately exercisable, expire in nine-months and have an exercise price of $0.18 per share. In addition, the Company issued 1,701,000 Series FF warrants to purchase 1,701,000 shares of common stock to the placement agent. The FF warrants are exercisable at any time on or after June 8, 2017 and expire on December 1, 2021 and have an exercise price $0.15625. The net proceeds to CEL-SCI from this offering was approximately $3.7 million, excluding any future proceeds that may be received from the exercise of the warrants.
Leaps it's not only in development they are you have a manufacturing patent proprietary injection patents.
analysts Recommendations: Net Element, Inc. (NASDAQ:NETE)
When it comes to the Analysis of a Stock, Price Target plays a vital role. 1 Analysts reported that the Price Target for Net Element, Inc. might touch $5.17 high while the Average Price Target and Low price Target is $90.7 and $5.17 respectively.
pharmaceutical stocks under stage two developmental news causes the most stock price movements . So when they released the 10 Q there should be information about the leaps stage 2 time frame.